ABSTRACTS-Myocardial Ischemia and Infarction of collateral vessels and exertion of ischemic preconditioning, but irreversible ischemia damages the heart such as necrosis or apoptosis. In the mice head, it is impossible to create low coronary flow (reversible) conditions, leading us to use canine hearts. However, it has been also difficult to examine the multiple gene expressions in canine hearts. To solve this difficulty, we succeeded in the development of canine DNA microarray, and tested the ability of this method to distinguish the subtle but essential differences in the pathophysiological conditions of the heart. About sixty cardiovascular related genes were cloned using PCR method from our newly developed beagle dog cDNA library, and spotted on CMToGAPS slides. PCR fragments were chosen to amplify the specific, non-overlapping open-reading frame of each cDNA. Using the arrays, we analyzed the expression profile of canine myooardium in two protocols, 1) necrotic myocardium caused by total LAD ligation for 3 hours (edual to mice necrosis model), and 2) ischemic myocardium of 50% LAD blood flow reduction (equal to angina pectoris of human). Three hours after 50 % coronary flow reduction, cardiovascular related genes were changed rapidly and the number of upregulated genes was much more than the case of complete coronary occlusion. These genes included ecto-5'-nucleotidase, endothelin-1, PAl-l, AT1 and AT2 receptors, PKC e. However, in the necrotic tissue, these gene expressions was almost lost. This indicates that ischemic damage without necrosis affects the gene expressions stronger on the survived myocardium than fatally damaged myocardium. These data suggest that canine DNA microarray provides the novel tool to assess the precise molecular events following the changes in physiological conditions.
Backround: In addition to their lipid lowering properties, statins improve endothelial function by increasing the activity of endothelial nitric oxide synthase (eNOS). We hypothesized, that by this mechanism statins may protect the myocardium from ischemic injury.
Methods: Anaesthetised rats underwent 30 min of coronary artery occlusion (CAd) followed by 180 min of reperfusion. Heart rate and arterial blood pressure were continuously monitored throughout the expedments. Plasma cholesterol concentrations were determined at the end of the experiments. Infarct size was measured by TTC staining and expressed as percentage of area at risk. Myocardial eNOS activity was measured by arginine to citrulline conversion assay. The rats were pretreated for one week either with cerivastatin (0.3 mgkg'ld "1) or placebo. In one set of experiments L-NAME (15 mgkg'l), an inhibitor of eNOS, was applicated 15 rain prior to CAd. Results: Cerivaatatin increased myocardial eNOS activity by 58% (12 -+ 1 to 19 + 2 pmol/mg/min, p,:0.05) and decreased infarct size by 49% (59 ± 7% to 29 ± 5%, p<0,05) without affecting hemodynamics or plasma cholesterol levels. Cardioprotection and uprogulation of eNOS activity were absent in rats co-treated with L-NAME. Conclusion: Statins reduce the extent of myocardial necrosis after acute ischemia/reperfusion injury by increasing myocardial eNOS activity.
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1099-30 Slmvastatin Restores Endothelial Nitric Oxide Mediated Vasorelaxation in Large Arteries After Myocardial Infarction
Kathrvn Bates. Steven Goldman, Mohemed Gaballa, SAVAHCS, Tucson, Arizona.
Congestive heart failure (CHF) after myocardial infarction (MI) is associated with diminished endothelial nitric oxide (NO)-mediated vasorelaxation. The 3-hydroxy-3 methylglutaryl CoA reductase inhibitors have been shown to modulate vascular tone, independent of their effects on lipid lowering. We hypothesized that simvastatin restores NO-dependent vasorelaxation after MI, produced by coronary artery ligation, via uprogulation of endothelial nitric oxide synthase (eNOS). We found that compared to normal arterial tissue incubated with culture medium only, incubation with 0.1 mM of simvastatin for 24 hours enhanced acetylcholine (ACh)-mediated vasorelaxation (P<0.05) with peak observed at 10 ,4 M (60~11% vs 33.7±7.8%, n=6; P<0.05). Compared to untreated rats, simvastatin increased eNOS protein content by over 200% (62.0~-t 4.0 % vs 21.6-+7.9 %, II/mg protein, P<0.05). In endothelial celts in culture, 10 mM and 20 mM of simvastatin increased eNOS Jevels by 114.7±39.9% and 212.0+75.0% H/rag protein, n=6, P<0.05, respectively, in CHF rats treated by oral gavage with simvastatin (20 mg/kg/day) for three weeks, mean artedal pressure (105 -+ 5.75 vs 96.5 -+ 10.SmmHg) and LV dP/dt (4288 + 672, vs 4091 -+ 1064 mmHg/sec, N--6) were decreased (P<0.05). Treatment of CHF rats with simvastatin reduced basal vasoconstriction and improved (P<0.05) the ACh-mediated vasorelaxation with a maximal response of 66.8 -+ 5.7% vs 32.6 -+ 6.8%, N=7, respectively. Inhibition of NO generation using 100 mM NG-nitro-L-arginine methyl ester (L-NAME) abolished the ACh-induced vasorelaxation in all rats. Our data suggest that JACC March 6, 2002
after 24 hour incubation with simvastatin in thoracic aodic segments and endothelial ceils in culture, endothelial dependent vasorelaxation is enhanced via up-regulation of endothelial eNOS. More importanUy, chronic treatment with simvastatin restores endothelial NO-dependent dysfunction in heart failure rats.
1099-31 Inhibitory Effects of the Novel Antagonist of Both GP lib/Ilia and Vitronectin Receptors on the Formation of Coronary Thromboemboli Caused by an Inhibition of Adenosine Receptors During Coronary Hypoperfusion in Dogs
Hiroshi Asanuma, Masafumi Kitakaze, Koichi Node, Shoji Saneda, Hisakazu Ogita, Seiji Takashima, Masanori Asakura, Tetsuo Minamino, Michihiko Tada, Masatsugu Hod, Osaka University Graduate School of Medicine, Suita, Japan, National Cardiovascular Center, Suita, Japan.
Background: Platelet glycoprotein (GP) lib/Ilia is a membrane receptor for fibrinogen and yon Willebrand factor, which plays an important role in platelet aggregation. Intogrin (xV~,3, vitronectin receptor, mediates adhesion and migration of many types of cells, such as vascular cells, and laukocytes. The activation of platelets and the formation of neutro-phU-platelet conjugates may lead to the development of thromboemboli. We have previously reported that endogenous adenosine inhibits P-selectin-dependerd formation of coronary thromboemboU during hypoperfusion in dogs, we examined whether the CP compound, a novel antagonist of both GP lib/Ilia and vitronectin receptors appears to inhibit the formation of thromboemboli during coronary hypopeffusion. Conclusion: Thus, we conclude that a novel antagonist of both GP lib/Ilia and vitronectin receptors attenuates platelet aggregation and the worsening of the severity of myocardial ischemia caused by the inhibitor of adenosine receptors. There appears the linkage between the signals of adenosine receptors and GP lib/Ilia or vitronectin receptors in platelet or coronary endothelial cells. BACKGROUND: Prompt opening of the infarct related adery is the treatment of choice for acute myocardial infarction (MI). A beneficial effect on left vantricular (LV) function often results even in patients in which little myocardium is salvage. We hypothesized that this phenomenon is dependent on adequate early microvascular perfusion. METHODS: Six sheep were subjected to 1 hour of ischemia followed by reperfusion (group 1). Six sheep underwent 6 hours of ischemia followed by reperfusion (group 2) and 7 sheep were infarcted without reperfusion (control). The ischemic region in all animals was 23% of the LV mass at the apex. Microvascular reflow was studied using LV long axis real time contrast echooardiography and microsphere injection dudng ischemia, 30 minutes after coronary repeffusion and at 2, 5, and 8 weeks. Echocardiography was used to assess changes in LV size and regional function throughout the study period. RESULTS: During coronary occlusion all animals demonstrated complete microvascular ischemia. After 30 minutes of coronary reperfusion, group 1 animals demonstrated microvascular reflow of the area at risk while group 2 animals demonstrated complete transmural non-reflow. At 2 weeks, both groups demonstrated complete return of transmural microvascular blood flow that persisted throughout the remainder of study. Control animals never achieved reflow in the infarct region. The area at risk remained akinetic in all groups throughout the study. At eight weeks LV end-systolic volume increased by 134% in control animals and by 114% in group 2 but was unchanged in group 1. CONCLUSION: Early microvascular reflow dramatically improves post-infarction LV remodeling independent of myocardial salvage. Background: Clotting factor Xlll has been shown to have a role in wound healing. We therefore studied healing after coronary artery ligation in FXIll KO and wild type mice.
Methods and Results:

1099-32
Early Microvascular Reflow Status After Infarct Reperfusion Determines Outcome of Postinfarction Remodeling Independent of Myocardial Salvage
1099-47
Impaired Healing in Factor
Methods: Magnetic Resonance Imaging was done 2 days after MI in a 7 T-Siospec usin~ an ECG-triggered Cine-FLASH-sequence: slice thickness 1 ram, echo-time 1.2 ms, resolution 230 ram. MI-size, left and right ventdcular (LV&RV) volumes, cardiac output (CO), ejection fraction (EF), wall thickness (WT) and -thickening (SWT) and LV mass were determined. To minimize bleeding from the thorecotomy wound, FXIII-free fibrin glue was applied.
Results and Conclusion:
All FXIII KO mice died within 3 to 5 days after MI, whereas wild type mice, that survived surgery, did not die. Dilatation after MI was not different between groups, but systolic global and regional function was impaired when compared to wildtype. Unchanged RV volumes suggest that hemorrhage from thoracotomy was not
